Table 1.

FDA approved and experimental drugs targeting copper metabolism in cancer treatment.

Drug Name	Mechanism	FDA Approval Status	Disease
D-penicillamine	Binds to copper and leads to its excretion	Yes	Wilson’s disease
Trientine	Binds to copper and leads to its excretion	Yes	Wilson’s disease
Zinc acetate	Blocks absorption of copper in the gut	Yes	Wilson’s disease
Tetrathiomolybdate	Binds to copper and leads to its excretion	No	N/A
Ethylenediaminetetraacetic acid (EDTA)	Binds to copper and leads to its excretion	Yes	Lead poisoning and iron overload
Dimercapto-propane sulfonate (DMPS)	Binds to copper and leads to its excretion	No	N/A
Dimercaptosuccinic acid (DMSA)	Binds to copper and leads to its excretion	Yes	Lead poisoning in children
Disulfiram (DSF)	Transports copper into cells and leads to its overload	Yes	Alcoholism
Elesclomol	Transports copper into cells and leads to its overload	No	N/A
Diacetyl-bis (N4-methylthiosemicarbazone) (ATSM)	Transports copper into cells and leads to its overload	No	N/A
Glyoxal-bis (N4-methylthiosemicarbazone) (GTSM)	Transports copper into cells and leads to its overload	No	N/A

N/A, Not applicable.